[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR040135A1 - NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE (BIII 890) - Google Patents

NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE (BIII 890)

Info

Publication number
AR040135A1
AR040135A1 ARP030101864A ARP030101864A AR040135A1 AR 040135 A1 AR040135 A1 AR 040135A1 AR P030101864 A ARP030101864 A AR P030101864A AR P030101864 A ARP030101864 A AR P030101864A AR 040135 A1 AR040135 A1 AR 040135A1
Authority
AR
Argentina
Prior art keywords
parenteral administration
crobenetine
biii
new formulation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Suspension/Interruption
Application number
ARP030101864A
Other languages
Spanish (es)
Inventor
Kruss Bernd Dr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR040135A1 publication Critical patent/AR040135A1/en
Suspension/Interruption legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Composición farmacéutica que contiene manitol y BIII890 o una de sus sales farmacológicamente aceptables. Reivindicación 6: Composición farmacéutica según una de las reivindicaciones 1 a 5, para la administración por vía parenteral.Claim 1: Pharmaceutical composition containing mannitol and BIII890 or a pharmacologically acceptable salt thereof. Claim 6: Pharmaceutical composition according to one of claims 1 to 5, for parenteral administration.

ARP030101864A 2002-05-29 2003-05-28 NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE (BIII 890) Suspension/Interruption AR040135A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223784A DE10223784A1 (en) 2002-05-29 2002-05-29 New formulation for parenteral administration of crobenetine

Publications (1)

Publication Number Publication Date
AR040135A1 true AR040135A1 (en) 2005-03-16

Family

ID=29432394

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101864A Suspension/Interruption AR040135A1 (en) 2002-05-29 2003-05-28 NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE (BIII 890)

Country Status (10)

Country Link
EP (1) EP1511487A1 (en)
JP (1) JP2005531573A (en)
AR (1) AR040135A1 (en)
AU (1) AU2003240699A1 (en)
CA (1) CA2487153A1 (en)
DE (1) DE10223784A1 (en)
PE (1) PE20040067A1 (en)
TW (1) TW200406205A (en)
UY (1) UY27824A1 (en)
WO (1) WO2003099280A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10223783A1 (en) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma New formulation for parenteral administration of a Na-channel blocker

Also Published As

Publication number Publication date
PE20040067A1 (en) 2004-03-30
EP1511487A1 (en) 2005-03-09
JP2005531573A (en) 2005-10-20
DE10223784A1 (en) 2003-12-11
UY27824A1 (en) 2003-12-31
TW200406205A (en) 2004-05-01
AU2003240699A1 (en) 2003-12-12
WO2003099280A1 (en) 2003-12-04
CA2487153A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
RS51569B (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
HRP20060240T3 (en) Intranasal formulation of rotigotine
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
EE200300033A (en) Cyclopentanoindoles, their use in the preparation of a medicament, and the pharmaceutical composition containing them
AR037592A1 (en) PHARMACEUTICAL FORMULATIONS OF 5,7,14-TRIAZATETRACICLO (10.3.1.02,11.04,9) -HEXADECA-2 (11), 3,5,7,9-PENTAENO
RS52169B (en) Stable laquinimod preparations
CY1111470T1 (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLYVERSERIN POLYMORPH A
CY1109880T1 (en) CaSR COMPONENT
HN2002000341A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETIS MELLITUS
BR0012951A (en) Selective retinoid agonists
BRPI0212298B8 (en) pharmaceutical composition comprising gabapentin or an analogue thereof and (alpha)-aminoamide and its analgesic use
CL2009000980A1 (en) Use of (s) -n- (2- (1,6,8-tetrahydro-2h-inden [5,4-b] furan-8-yl) ethyl] propionamide in combination with one or more drugs selected from a group defined to prepare a drug useful for the prevention or treatment of depression or anxiety disorders (divisional application 749-2006).
BR0112847A (en) Use of a solid dosage form
AR031649A1 (en) DRONEDARONA PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION
BR0113165A (en) 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods
BR0013582A (en) Selective retinoid agonists for rar
AR087240A2 (en) PHARMACEUTICAL COMPOSITIONS THAT HAVE EPINASTINE AND PSEUDOEFEDRINE
BR0114395A (en) Pharmaceutical composition for oral supply administration
GT200400134A (en) EMULSIONING SYSTEMS CONTAINING DERIVATIVES OF AZETIDINE
TN2010000008A1 (en) Oral pharmaceutical solutions containing telbivudine
AR040135A1 (en) NEW FORMULATION FOR PARENTERAL ADMINISTRATION OF CROBENETINE (BIII 890)
AR004503A1 (en) USE OF L-CARNITINE, L-ACRYLIC L-CARNITINES IN WHICH THE ACIL, LINEAR OR BRANCHED GRUO, HAS BETWEEN 2 AND 6 CARBON ATOMS AND THEIR ACCEPTABLE SALES, AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS
AR023452A1 (en) USE OF OSANETANT FOR PREPARATION OF USEFUL MEDICINES IN THE TREATMENT OF HUMOR DISORDERS
UY27920A1 (en) COMBINATIONS OF EPINASTINE, PSEUDOEFEDRINE AND METHYLEDHEDRINE AS NEW PHARMACEUTICAL FORMULATIONS
SE0203817D0 (en) New composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure